维妥珠单抗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "维妥珠单抗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
1st place
1st place
3rd place
8th place
3,257th place
3,896th place
5,225th place
4,888th place
low place
low place
ama-assn.org
- Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
books.google.com
- Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
clinicaltrials.gov
- Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
doi.org
- Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
- Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491
. PMID 19710501. doi:10.1182/blood-2009-06-228890. - Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.
healio.com
- FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015 [2024-04-18]. （原始内容存档于2019-09-07）.
nih.gov
ncbi.nlm.nih.gov
- Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. October 2009, 114 (18): 3864–71. PMC 2773491 . PMID 19710501. doi:10.1182/blood-2009-06-228890.
- Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology. June 2015, 169 (5): 701–10. PMC 7297055 . PMID 25847298. doi:10.1111/bjh.13354.
web.archive.org
- Zibelman M, Borghaei H, Olszanski AJ. Harnessing Innate Immunity. Dubel S, Reichert JM (编). Handbook of Therapeutic Antibodies 2nd. John Wiley & Sons. 2014: 791 [2024-04-18]. ISBN 978-3-527-68244-7. doi:10.1002/9783527682423.ch27. （原始内容存档于2024-04-18）.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab （页面存档备份，存于互联网档案馆）, American Medical Association.
- FDA grants orphan drug designation to veltuzumab for ITP. HemOnc Today. Healio.com. August 4, 2015 [2024-04-18]. （原始内容存档于2019-09-07）.